Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Assets Average (2021 - 2025)

Historic Assets Average for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Q3 2025 value amounting to $873.1 million.

  • Maravai Lifesciences Holdings' Assets Average fell 3585.03% to $873.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $873.1 million, marking a year-over-year decrease of 3585.03%. This contributed to the annual value of $1.2 billion for FY2024, which is 3379.71% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Assets Average is $873.1 million, which was down 3585.03% from $928.4 million recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Assets Average peaked at $2.3 billion during Q1 2023, and registered a low of $873.1 million during Q3 2025.
  • In the last 5 years, Maravai Lifesciences Holdings' Assets Average had a median value of $1.7 billion in 2021 and averaged $1.7 billion.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Assets Average surged by 5106.07% in 2022 and then crashed by 3993.8% in 2024.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Assets Average stood at $1.9 billion in 2021, then increased by 18.84% to $2.3 billion in 2022, then decreased by 17.13% to $1.9 billion in 2023, then plummeted by 39.11% to $1.1 billion in 2024, then dropped by 23.63% to $873.1 million in 2025.
  • Its last three reported values are $873.1 million in Q3 2025, $928.4 million for Q2 2025, and $984.0 million during Q1 2025.